{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:29:06Z","timestamp":1794022146563,"version":"4.8.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biomedical Research Centre Award"},{"DOI":"10.13039\/501100000762","name":"Imperial College Healthcare NHS Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000762","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health Research Senior Investigator"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Visit-to-visit systolic blood pressure variability (BPV) is an important predictor of cardiovascular (CV) outcomes. The long-term effect of a period of blood pressure (BP) control, but with differential BPV, is uncertain. Morbidity and mortality follow-up of UK participants in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure-Lowering Arm has been extended for up to 21 years to determine the CV impact of mean systolic blood pressure (SBP) control and BPV during the trial, and amongst those allocated to amlodipine- and atenolol-based treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eight thousand five hundred and eighty hypertensive participants (4305 assigned to amlodipine \u00b1 perindopril-based and 4275 to atenolol \u00b1 diuretic-based treatment during the in-trial period (median 5.5 years) were followed for up to 21 years (median 17.4 years), using linked hospital and mortality records. A subgroup of participants (n = 2156) was followed up 6 years after the trial closure with a self-administered questionnaire and a clinic visit. In-trial mean SBP and standard deviation of visit-to-visit SBP as a measure of BPV, were measured using &amp;gt;100 000 BP measurements. Cox proportional hazard models were used to estimate the risk [hazard ratios (HRs)], associated with (i) mean with SBP and BPV during the in-trial period, for the CV endpoints occurring after the end of the trial and (ii) randomly assigned treatment to events following randomization, for the first occurrence of pre-specified CV outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Using BP data from the in-trial period, in the post-trial period, although mean SBP was a predictor of CV outcomes {HR per 10\u2005mmHg, 1.14 [95% confidence interval (CI) 1.10\u20131.17], P &amp;lt; .001}, systolic BPV independent of mean SBP was a strong predictor of CV events [HR per 5\u2005mmHg 1.22 (95% CI 1.18\u20131.26), P &amp;lt; .001] and predicted events even in participants with well-controlled BP. During 21-year follow-up, those on amlodipine-based compared with atenolol-based in-trial treatment had significantly reduced risk of stroke [HR 0.82 (95% CI 0.72\u20130.93), P = .003], total CV events [HR 0.93 (95% CI 0.88\u20130.98), P = .008], total coronary events [HR 0.92 (95% CI 0.86\u20130.99), P = .024], and atrial fibrillation [HR 0.91 (95% CI 0.83\u20130.99), P = .030], with weaker evidence of a difference in CV mortality [HR 0.91 (95% CI 0.82\u20131.01), P = .073]. There was no significant difference in the incidence of non-fatal myocardial infarction and fatal coronary heart disease, heart failure, and all-cause mortality.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Systolic BPV is a strong predictor of CV outcome, even in those with controlled SBP. The long-term benefits of amlodipine-based treatment compared with atenolol-based treatment in reducing CV events appear to be primarily mediated by an effect on systolic BPV during the trial period.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehad814","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T05:47:24Z","timestamp":1706680044000},"page":"1159-1169","source":"Crossref","is-referenced-by-count":58,"title":["Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-8503","authenticated-orcid":false,"given":"Ajay","family":"Gupta","sequence":"first","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London , UK"},{"name":"National Heart & Lung Institute, Imperial College London , Room 333, ICTEM Building, Du Cane Road, London W12 0NN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4816-8991","authenticated-orcid":false,"given":"William N","family":"Whiteley","sequence":"additional","affiliation":[{"name":"Centre for Clinical Brain Sciences, University of Edinburgh , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Godec","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Queen Mary University of London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Rostamian","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , Room 333, ICTEM Building, Du Cane Road, London W12 0NN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cono","family":"Ariti","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , Room 333, ICTEM Building, Du Cane Road, London W12 0NN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Mackay","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , Room 333, ICTEM Building, Du Cane Road, London W12 0NN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Whitehouse","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , Room 333, ICTEM Building, Du Cane Road, London W12 0NN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Janani","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit, Imperial College London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-997X","authenticated-orcid":false,"given":"Neil R","family":"Poulter","sequence":"additional","affiliation":[{"name":"School of Public Health, Imperial College London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0421-2409","authenticated-orcid":false,"given":"Peter S","family":"Sever","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Imperial College London , Room 333, ICTEM Building, Du Cane Road, London W12 0NN , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ASCOT-10 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jehad","family":"Aldegather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Collier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Delles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dyker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hildick-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arni","family":"Kristinsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Milward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"O\u2019Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Reckless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Shakespeare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soran","family":"Handrean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"2024040212470805300_ehad814-B1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(10)60308-X","article-title":"Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension","volume":"375","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"key":"2024040212470805300_ehad814-B2","doi-asserted-by":"crossref","first-page":"i4098","DOI":"10.1136\/bmj.i4098","article-title":"Blood pressure variability and cardiovascular disease: systematic review and meta-analysis","volume":"354","author":"Stevens","year":"2016","journal-title":"BMJ"},{"key":"2024040212470805300_ehad814-B3","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial","volume":"366","author":"Dahl\u00f6f","year":"2005","journal-title":"Lancet"},{"key":"2024040212470805300_ehad814-B4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(05)67186-3","article-title":"Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)","volume":"366","author":"Poulter","year":"2005","journal-title":"Lancet"},{"key":"2024040212470805300_ehad814-B5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1474-4422(10)70066-1","article-title":"Effects of \u03b2-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke","volume":"9","author":"Rothwell","year":"2010","journal-title":"Lancet Neurol"},{"key":"2024040212470805300_ehad814-B6","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(18)31776-8","article-title":"Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial","volume":"392","author":"Gupta","year":"2018","journal-title":"Lancet"},{"key":"2024040212470805300_ehad814-B7","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1161\/STROKEAHA.120.033489","article-title":"Long-term incidence of stroke and dementia in ASCOT","volume":"52","author":"Whiteley","year":"2021","journal-title":"Stroke"},{"key":"2024040212470805300_ehad814-B8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","article-title":"Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT Investigators","volume":"19","author":"Sever","year":"2001","journal-title":"J Hypertens"},{"key":"2024040212470805300_ehad814-B9","doi-asserted-by":"crossref","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"2024040212470805300_ehad814-B10","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"2024040212470805300_ehad814-B11","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2024040212470805300_ehad814-B12","doi-asserted-by":"crossref","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"key":"2024040212470805300_ehad814-B13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(10)60235-8","article-title":"Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis","volume":"375","author":"Webb","year":"2010","journal-title":"Lancet"},{"key":"2024040212470805300_ehad814-B14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/HJH.0000000000003033","article-title":"Effects of dihydropyridine calcium channel blockers on blood pressure variability in the SPRINT trial: a treatment effects approach","volume":"40","author":"de Havenon","year":"2022","journal-title":"J Hypertens"},{"key":"2024040212470805300_ehad814-B15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/ajh.2008.325","article-title":"Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia","volume":"22","author":"Cohn","year":"2009","journal-title":"Am J Hypertens"},{"key":"2024040212470805300_ehad814-B16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"key":"2024040212470805300_ehad814-B17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.110.160291","article-title":"Persistence of mortality reduction after the end of randomised therapy in clinical trials of blood pressure-lowering medications","volume":"56","author":"Kostis","year":"2010","journal-title":"Hypertension"},{"key":"2024040212470805300_ehad814-B18","first-page":"1138","article-title":"Longer-term all-cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomised clinical trial","volume":"7","author":"Jaeger","year":"2022","journal-title":"JAMA"},{"key":"2024040212470805300_ehad814-B19","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2024040212470805300_ehad814-B20","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ajh\/hpt040","article-title":"Associations of aortic distensibility and arterial elasticity with long-term visit-to-visit blood pressure variability: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"26","author":"Shimbo","year":"2013","journal-title":"Am J Hypertens"},{"key":"2024040212470805300_ehad814-B21","author":"NICE clinical guideline [CG127]"},{"key":"2024040212470805300_ehad814-B22","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"2013","author":"Mancia","year":"2013","journal-title":"J Hypertens"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/13\/1159\/57138401\/ehad814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/13\/1159\/57138401\/ehad814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T14:09:52Z","timestamp":1712066992000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/13\/1159\/7590543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":22,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,1,31]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad814","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,1]]},"published":{"date-parts":[[2024,1,31]]}}}